Log In
BCIQ
Print this Print this
 

VPI-2690B

  Manage Alerts
Collapse Summary General Information
Company Vascular Pharmaceuticals Inc.
DescriptionHumanized mAb against integrin alpha(5)beta (3) (CD49e/CD61)
Molecular Target Integrin alpha(5)beta(3) (CD49e/CD61)
Mechanism of ActionAntibody
Therapeutic ModalityBiologic: Antibody
Latest Stage of DevelopmentPhase II
Standard IndicationDiabetic nephropathy
Indication DetailsTreat diabetic nephropathy
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

09/12/2012

Undisclosed

0

Undisclosed

Get a free BioCentury trial today